Nyrada (ASX:NYR) Research & Development: A$4.23 Mil (TTM As of Dec. 2025)


ASX:NYR Nyrada Inc ASX:NYR
25 GF Score
Price A$0.40
! 1 Warning Sign
View Full Analysis

What is Nyrada Research & Development?

Nyrada ASX:NYR -9.09% 25 Research & Development is A$4.23 Mil as of Dec. 2025. GuruFocus rates ASX:NYR with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nyrada's Research & Development for the six months ended in Dec. 2025 was A$1.66 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$4.23 Mil.

Nyrada  (ASX:NYR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nyrada Research & Development Related Terms

Nyrada Research & Development Historical Data

* Premium members only.

The historical data trend for Nyrada's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada Research & Development Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 2.18 1.84 6.41 2.03 4.38

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 1.14 1.81 2.57 1.66
ASX:NYR
25GF Score
Nyrada Inc ASX:NYR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$4.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$4.23 Mil mean?
Nyrada (ASX:NYR) has a Research & Development of A$4.23 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Nyrada and its competitors.
Is Nyrada's Research & Development too high?
Nyrada's current Research & Development is A$4.23 Mil. Overall, Nyrada has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's Research & Development compare to VRTX and REGN?
Nyrada's Research & Development of A$4.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nyrada and its competitors. Nyrada's current Research & Development is A$4.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current Research & Development of A$4.23 Mil. The current Research & Development is A$4.23 Mil. Nyrada's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current Research & Development is A$4.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
25GF Score

Get the complete analysis for ASX:NYR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.40
Price